Economic Overview - The U.S. economy added 353,000 jobs in January, significantly exceeding the Dow Jones estimate of 185,000 [1] - Average hourly earnings increased by 0.6% month-over-month and 4.5% year-over-year, surpassing economists' expectations [1] Market Sentiment - Traders are less enthusiastic about strong economic data as it reduces the urgency for the Federal Reserve to cut interest rates [1][2] - There is a perception that some traders prefer a weak economy to facilitate rate cuts rather than supporting long-term earnings growth [2] Biotech Sector Performance - The biotech sector is experiencing significant profit-taking, with notable gains reported by Luke Lango's trading service, High Velocity Stocks [2][3] - Recent profits include 30% gains from Autolus Therapeutics, 40% from Amneal Pharmaceuticals, and 100% from Ardelyx [3] Future Outlook for Biotech - A "2024 Biotech Boom" is anticipated, driven by lower interest rates and improving risk sentiment [4] - The prospect of lower interest rates is expected to positively impact biotech R&D funding, which is often debt-financed [4] Impact of Artificial Intelligence - AI is poised to revolutionize drug discovery economics by increasing success rates and reducing costs and timelines for clinical trials [6] - Hypothetical scenarios suggest that AI could lower average drug development costs from $2.6 billion to less than $1.5 billion [6][7] Stage Analysis Framework - The stage analysis framework focuses on stock price action and momentum, identifying stocks on the verge of breakout [8][9] - The biotech sector is currently in Stage-1 consolidation, with potential for a Stage-2 breakout, which could lead to significant gains [10][11] Investment Strategies - Investors can choose between a buy-and-hold strategy for long-term exposure to biotech or a more active trading approach based on price momentum [12][13] - A conservative approach suggests waiting for the SPDR S&P Biotech ETF (XBI) to break above its Stage-1 resistance level of approximately $95 before initiating trades [13]

ADC Therapeutics (ADCT) is a commercial-stage biotech company focused on developing novel antibody-drug conjugates (ADC) to treat patients with hematologic malignancies and solid tumors.Currently, ADC Therapeutics has only one marketed drug in its portfolio, Zynlonta, which the FDA approves to treat relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in the third or later-line setting.Management is also evaluating Zynlonta in combination with other agents and earlier lines of therapy. Apart f ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ADC Therapeutics SA (ADCT) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.ADC Therapeutics SA is a member of our Medical group, which includes 1077 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 dif ...

Core Insights - The cancer drug market, particularly antibody-drug conjugates (ADCs), is experiencing significant growth and interest from various companies, as highlighted during the JPMorgan Healthcare Conference in San Francisco [1][2] - Johnson & Johnson's recent $2 billion acquisition of Ambrx Biopharma is indicative of the strategic moves companies are making to enhance their ADC pipelines, with other major players like Pfizer and Merck also engaging in ADC-related deals [2] - Analysts predict continued advancements and deal-making in the ADC space, driven by increased confidence in the technology and the potential for substantial profits, with ADCs projected to represent $31 billion of the $375 billion global cancer market by 2028 [3] Industry Trends - The enthusiasm for ADCs is fueled by their ability to specifically target cancer cells while minimizing damage to healthy cells, contrasting with traditional chemotherapy [1] - The ADC market was valued at approximately $9.7 billion in 2023, indicating a robust foundation for future growth [3] - The fear of missing out (FOMO) among companies not yet involved in the ADC market is likely to drive further entries and investments into this sector [2][3]

ZYNLONTA®1 4Q 2023 net sales expected to be ~$16.5 million, a double-digit percentage increase as compared to 3Q 2023 LOTIS-7: Study of ZYNLONTA in combination with bispecifics cleared first dosing cohort​ with no DLT and with early signs of efficacy ADCT-601 (targeting AXL): Reached MTD and currently in dose optimization; Early signs of antitumor activity in both monotherapy and in combination Multiple data catalysts expected in 2024 and with a cash runway now expected into 4Q 2025 LAUSANNE, Switzerland, ...

Love Employee Overview ADCs - antigen-drug conjugants - are among the hottest developments in cancer treatments. In combination with other drugs, they hold the promise of replacing chemotherapy on a whole host of cancers, because, unlike chemo, which is systemic and comes with severe side effects, ADCs target specific tumors with minimal impacts on healthy tissue. Sometimes called "Smart chemo," and "Cancer guided missiles," ADC's work by delivering a combination of an antibody and a cancer-cell killer to a ...

ADC Therapeutics SA (NYSE:ADCT) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Eugenia Litz - Vice President of Investor Relations and Corporate Communications Ameet Mallik - Chief Executive Officer Kristen Herrington-Smith - Chief Commercial Officer Mohamed Zaki - Chief Medical Officer Pepe Carmona - Chief Financial Officer Conference Call Participants Naureen Quibria - Capital One Securities Brian Cheng - JPMorgan Operator Welcome to the ADC Therapeutics Third Quarter 20 ...

Exhibit 99.1 Unaudited IFRS Condensed Consolidated Interim Financial Statements as of and for the three and nine months ended September 30, 2023. Condensed Consolidated Interim Statement of Operations 2 Condensed Consolidated Interim Statement of Comprehensive Loss 3 Condensed Consolidated Interim Balance Sheet 4 Condensed Consolidated Interim Statement of Changes in Equity 5 Condensed Consolidated Interim Statement of Cash Flows 7 Notes to the Condensed Consolidated Interim Financial Statements 8 ADC Thera ...

ADC Therapeutics SA (NYSE:ADCT) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Eugenia Litz - Vice President of Investor Relations and Corporate Communications Ameet Mallik - Chief Executive Officer Kristen Herrington-Smith - Chief Commercial Officer Mohamed Zaki - Chief Medical Officer Pepe Carmona - Chief Financial Officer Conference Call Participants Kelly Shi - Jefferies Naureen Quibria - Capital One Securities Michael Riad - Morgan Stanley Brian Chan - JPMorgan Operator ...

2Q 2023 Earnings Call Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or ADC Therapeutics or any officer, director, employee, agent or advisor of ADC Therapeutics. This presentation does not purport to be ...